ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 149

Natural Language Processing in the Evaluation of Gout Quality Indicators

Gail S. Kerr1, J. Steuart Richards2, Carl A. Nunziato3, Olga V. Patterson4, Scott L. DuVall5, David D. Maron6 and Richard L. Amdur7, 1Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, 2Rheumatology, Washington DC VA and Georgetown University, Washington, DC, 3Rheumatology, Washington DC VA and Howard University, Washington, DC, 4VA Salt Lake City Health Care System and University of Utah School of Medicine, UT, 5VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, 6Research Department, Washington DC VA Medical Center, Washington, DC, 7Washington DC VA and Georgetown Unviversity, Washington, DC

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: gout and quality of care

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Gout is a common inflammatory arthritis with significant impact on both patients and health care systems. Despite ACR/EULAR management guidelines and gout quality indicators (QI) developed to improve outcomes, standard of care is often suboptimal and infrequently measured. We evaluated the standard of care of in a cohort of Veterans Affairs (VA) gout patients, using QI that include medication, laboratory and counseling criteria.

Methods: During a 4 year period, VA administrative data was used to identify gout outpatients (ICD 9 codes: 274.xx and at least 2 related visits). QIs assessed were QI 1: patients with creatinine clearance < 60 ml/min, initial allopurinol dose to be < 300 mg/day; QI 2: uric acid (UA) within 6 months of allopurinol start; QI 3: if on colchicine CBC, CPK done within 6 months; QI 4: counseling on gout specific diet, weight loss and alcohol consumption. For QI 4, natural language processing (NLP), a technique that analyzes large amounts of text to identify key words and/or phrases, was used to extract dietary, alcohol and weight loss counseling data from electronic medical records. Data collected were socio- demographics, comorbidities [HTN, DM, CVD, hyperlipidemia, obesity and chronic kidney disease (CKD)] and number of rheumatology outpatient visits for gout. QI compliance versus non-compliance was compared using chi-square analyses.

Results: Of 2,280 gout patients, 2,260 (99.1%) were male, with mean age of 66.8 years. Comorbidities were common: HTN in 2,102 (92.2%); Obesity in 1,578 (69.2%); CVD in 1,384 (60.7%); hyperlipidemia in 1,170 (51.3%); DM in 1,075 (47.1%); and CKD in 748 (33.8%). Most 1,587 (69.6%) had at least one rheumatology outpatient visit, and more than half received specific gout therapy: colchicine was dispensed to 1424 (62.5%) and allopurinol to 1,336 (58.6%) patients. Compliance with each QI was as follows: QI 1: 92.1%; QI 2: 44.8%; QI 3: CBC monitoring 70%; but only 6.3% for both CBC and CPK (only 1 patient had CPK without CBC). For QI 4, there was counseling for weight loss in 1008 (44.2%), diet in 390 (17.1%), alcohol in 137 (6.0%) and 51 (2.2%) had counseling on all 3 elements. Of those on new allopurinol prescriptions, target serum uric acid (< 6 mg/dl) was achieved in 64 (30.1%) patients within one year. Compared with non-compliant patients, patients compliant with QI 2 had more rheumatology visits (3.5 vs. 2.6; p< 0.001), while those compliant with QI 3 (CBC) were older (67.3 vs 64.9 years p<0.001) and had more CKD (p<0.001), DM (p<0.001) and CVD (p<0.001). Patients with DM, obesity, and hyperlipidemia were more often counseled on diet compared to those without comorbidities.  Alcohol counseling was less frequent in gout patients with hyperlipidemia (p= 0.024) and DM (p=0.012) compared to patients without comorbidities.

Conclusion: In our study cohort, compliance with QI for uric acid and CPK monitoring were subpar. In gout patients, specific dietary counseling appeared to be directed by other comorbidities. NLP proved a valuable tool for evaluating dietary QI in patients with gout.


Disclosure:

G. S. Kerr,

Savient, Ardea,

;

J. S. Richards,

Ardea,

9,

Savient,

9;

C. A. Nunziato,
None;

O. V. Patterson,
None;

S. L. DuVall,

Anolinx LLC,

2,

Genentech Inc.,

2,

F. Hoffmann-La Roche Ltd,

2,

Amgen Inc,

2,

Shire PLC,

2,

Mylan Specialty PLC,

2;

D. D. Maron,
None;

R. L. Amdur,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/natural-language-processing-in-the-evaluation-of-gout-quality-indicators/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology